CTOs on the Move

StriVectin

www.strivectin.com

 
Our mission is simple. Deliver the most high-performance skincare and haircare solutions powered by the latest clinical advances to transform the look of your skin and hair. At the center of every formula is patented, proprietary NIA-114 technology that supercharges StriVectin`s clinically proven, award winning products.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.strivectin.com
  • 601 West 26th Street Suite 1505
    New York, NY USA 10001
  • Phone: 800.430.0227

Executives

Name Title Contact Details

Similar Companies

Unchained Labs

Unchained Labs is committed to building the first cool biologics tools company. One with products that`ll make a real difference in the research scientists do every day. One that UNleashes tools that help them characterize their biologics better. Founded in January 2015, we have raised $31M of venture capital and have purchased two product lines. First, we let loose the UNit, the world`s first and only multiplex protein stability platform. Next we landed another big win with ICD, the world`s first quantitative stability predictor. With these two products, we have established ourselves as the experts in protein stability

Apria Healthcare

Apria Healthcare is a Jacksonville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cure International

Cure International is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Lemoyne, PA. To find more information about Cure International, please visit www.cureinternational.org

Xenon Pharmateuticals

Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.

Bridges Health

Bridges Health (formerly IRC Innovative Rehabilitation Consultants) has been serving the community since 1997.